What's Happening?
Immunome, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for varegacestat, an investigational treatment for adults with desmoid tumors. The FDA has set a Prescription Drug User Fee Act (PDUFA)
target action date of April 28, 2027. Varegacestat, a gamma secretase inhibitor, showed promising results in the Phase 3 RINGSIDE trial, significantly improving progression-free survival and other key endpoints. Desmoid tumors are aggressive, non-metastatic soft tissue tumors that can cause significant pain and disability.
Why It's Important?
The FDA's acceptance of the NDA for varegacestat marks a critical step forward in providing a new treatment option for patients with desmoid tumors, a condition with limited therapeutic options. If approved, varegacestat could offer a significant improvement in managing the disease, potentially reducing the clinical burden and improving quality of life for patients. This development also highlights Immunome's role in advancing targeted cancer therapies and underscores the importance of continued innovation in oncology to address unmet medical needs.
What's Next?
With the NDA accepted, Immunome will work closely with the FDA during the review process, aiming for approval by the PDUFA date in 2027. The company also plans to submit a Marketing Authorization Application to the European Medicines Agency by the end of 2026. The outcome of these regulatory reviews will determine varegacestat's availability to patients and its potential impact on the treatment landscape for desmoid tumors. The medical community and patients will be closely monitoring the progress of this application.
